☆ 4.6 Article

Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)*

ESMO OPEN (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Endocrinology & Metabolism

Sex and Gender Differences in Anticancer Treatment Toxicity: A Call for Revisiting Drug Dosing in Oncology

Berna C. Ozdemir et al.

Summary: The practice of oncology has undergone significant changes in the past decade, with the introduction of molecular tumor profiling and immunotherapies. There is a need to explore personalized dosing strategies that take into account the patient's sex and gender differences.

ENDOCRINOLOGY (2022)

添加到收藏夹

Article Oncology

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)

Dominik Paul Modest et al.

Summary: The PANAMA trial investigated the efficacy of adding panitumumab to maintenance therapy in patients with RAS wild-type metastatic colorectal cancer, and found that combining panitumumab with fluorouracil and folinic acid could significantly improve progression-free survival in these patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.

Takayuki Yoshino et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Trends in Women's Leadership of Oncology Clinical Trials

Ithai Waldhorn et al.

Summary: This study examined the representation of women as principal investigators (PIs) in oncology clinical trials between 1999 and 2019 and found that while the proportion of women PIs has increased over time, there are still disparities in non-Western countries, advanced study phases, and industry-funded trials. The gender of the PI was also found to be associated with the enrollment of female subjects.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database

Anna D. Wagner et al.

Summary: The study compared the toxicity of fluoropyrimidine-based adjuvant chemotherapy between male and female patients with colon cancer after surgery, finding that women are consistently at increased risk of major toxicities.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Sex- and Gender-Based Pharmacological Response to Drugss

Franck Mauvais-Jarvis et al.

Summary: This study examines how biological sex influences the pharmacokinetics and pharmacodynamics of drugs, providing examples of common drugs affecting specific organ systems. The study also explores how the gender of physicians and patients can impact the therapeutic response to drugs.

PHARMACOLOGICAL REVIEWS (2021)

添加到收藏夹

Article Oncology

Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110)

Kathrin Heinrich et al.

Summary: The study compared sequential versus initial irinotecan in combination with fluoropyrimidine plus bevacizumab in patients with metastatic colorectal cancer, finding an interaction of treatment, gender, and RAS mutational status.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study

A. Raimondiy et al.

Summary: The study showed no significant differences in efficacy, safety, and quality of life between elderly and younger patients receiving anti-EGFR treatment. Female patients had a higher incidence of severe adverse events, while male patients were more likely to experience skin rash and hypomagnesemia.

ESMO OPEN (2021)

添加到收藏夹

Review Oncology

Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials

F. Conforti et al.

Summary: In advanced non-small-cell lung cancer patients expressing high PD-L1 levels, the effectiveness of anti-PD-1/anti-PD-L1 monotherapy was significantly greater in men compared to women. This suggests the need for further prospective trials testing sex-based tailored immunotherapy strategies.

ESMO OPEN (2021)

添加到收藏夹

Article Medicine, General & Internal

Analysis of Female Enrollment and Participant Sex by Burden of Disease in US Clinical Trials Between 2000 and 2020

Jecca R. Steinberg et al.

Summary: This study found that sex differences in clinical trials varied by disease category, with male and female participants underrepresented in different medical fields. Although progress has been made in sex equity, the persistence of sex bias in clinical trials within medical fields has negative consequences for the health of all individuals.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Article Oncology

Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database.

Anna Dorothea Wagner et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis

Fabio Conforti et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)

添加到收藏夹

Article Oncology

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial

Filippo Pietrantonio et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Gender medicine and oncology: report and consensus of an ESMO workshop

A. D. Wagner et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Review Medicine, General & Internal

Colorectal cancer

Evelien Dekker et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials

Dominik Paul Modest et al.

INTERNATIONAL JOURNAL OF CANCER (2019)

添加到收藏夹

Article Oncology

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled StudyXELAVIRI (AIO KRK0110)

Dominik Paul Modest et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

Dominik P. Modest et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Quantifying Sex Bias in Clinical Studies at Scale With Automated Data Extraction

Sergey Feldman et al.

JAMA NETWORK OPEN (2019)

添加到收藏夹

Article Oncology

Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial

Sabine Tejpar et al.

EUROPEAN JOURNAL OF CANCER (2018)

添加到收藏夹

Review Oncology

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

Fabio Conforti et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

A. Grothey et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Letter Oncology

Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group

Valerie Cristina et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Review Oncology

A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK

Alan White et al.

BMC CANCER (2018)

添加到收藏夹

Article Medicine, General & Internal

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial

Alan P. Venook et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

添加到收藏夹

Article Oncology

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

D. Arnold et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Oncology

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

E. Van Cutsem et al.

ANNALS OF ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254

Gita Thanarajasingam et al.

LANCET ONCOLOGY (2016)

添加到收藏夹

Letter Oncology

Women at a Disadvantage in Fluorouracil Treatment

Joseph Ciccolini et al.

JAMA ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer

Eric Van Cutsem et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Oncology

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Chiara Cremolini et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

J. Y. Douillard et al.

ANNALS OF ONCOLOGY (2014)

添加到收藏夹

Article Oncology

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Volker Heinemann et al.

LANCET ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study

F. Mueller et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)

添加到收藏夹

Article Pharmacology & Pharmacy

Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors

Huali Wu et al.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)

添加到收藏夹

Article Oncology

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

David Cunningham et al.

LANCET ONCOLOGY (2013)

添加到收藏夹

Review Oncology

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

Mario E. Lacouture et al.

SUPPORTIVE CARE IN CANCER (2011)

添加到收藏夹

Article Oncology

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Jean-Yves Douillard et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

添加到收藏夹

Article Medicine, General & Internal

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Eric Van Cutsem et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

添加到收藏夹

Article Oncology

OPTIMOX1:: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer -: A GERCOR study

C Tournigand et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

添加到收藏夹

Article Oncology

Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma

K Chansky et al.

CANCER (2005)

添加到收藏夹

Article Oncology

Factors affecting the pharmacokinetics of CPT-11: The body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11

T Miya et al.

INVESTIGATIONAL NEW DRUGS (2001)

添加到收藏夹

Article Oncology

Sex differences in fluorouracil-induced stomatitis

JA Sloan et al.

JOURNAL OF CLINICAL ONCOLOGY (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.